21903_Reducing LDL-C and Cardiovascular Risk with Nonstatin Therapy: From Evidence to Practice

In this symposium, lipid experts Dr. Robert Giugliano, Dr. Marc Sabatine, and Dr. James Underberg will describe best practices for internists in managing LDL-C and reducing the risk for major cardiovascular events with the addition of nonstatin therapy.

Low-density lipoprotein cholesterol (LDL-C) is a primary cause of atherosclerosis and remains a central focus of cardiovascular risk reduction. Among lipid-lowering drugs, statins are the cornerstone of therapy. Clinical practice guidelines have identified major statin benefit groups for whom the atherosclerotic cardiovascular disease (ASCVD) risk reduction clearly outweighs the risk of adverse events. Even among those treated with high-intensity statins, many adults with cardiovascular disease are not achieving recommended LDL-C levels; while intensifying statin therapy provides additional cardiovascular risk reduction, residual cardiovascular risk remains. Certain patient populations may benefit from the addition of nonstatin, LDL-C-lowering therapy; clinical trials have demonstrated benefits in high-risk patient populations with the use of ezetimibe and PCSK9 inhibitors. In this symposium, lipid experts Dr. Robert Giugliano, Dr. Marc Sabatine, and Dr. James Underberg will describe best practices for internists in managing LDL-C and reducing the risk for major cardiovascular events with the addition of nonstatin therapy.

Login to your Account